Ozempic and Wegovy | Forbes-Featured Researcher Investigates Side Effects of Weight Loss Drugs

Medications like Ozempic and Wegovy are being used for weight loss, but what are the risks when it comes to side effects? Medical Researcher Mohit Sodhi, recently featured in Forbes' Top 30 under 30 in Healthcare joins the All Things Fitness and Wellness podcast for our debut exercise snack. Sodhi gained global attention for unveiling the heightened risks associated with Ozempic and similar weight loss drugs. With an impressive portfolio of over 35 peer-reviewed publications, Sodhi delves into the latest study findings.

🔍 Study Focus:
This groundbreaking study compared the use of GLP-1 agonists for weight loss. The results revealed an increased risk of pancreatitis, gastroparesis, and bowel obstruction, though not biliary disease.

🤔 Implications:
Given the widespread use of these drugs, albeit rare, patients considering them for weight loss must weigh the risks against the benefits. This discussion sheds light on how the risk-benefit calculation may differ for those seeking weight loss compared to those using these drugs for diabetes management.

📌 Limitations:
While all GLP-1 agonist users in the study had a record for obesity without diabetes, the study acknowledges uncertainties regarding whether GLP-1 agonists were exclusively used for weight loss.

New episodes of Exercise Snacks: Bite Size Science will drop every other Monday.
Connect with All Things Fitness and Wellness:
www.atfw.ca
https://www.instagram.com/allthingsfitnessandwellness/ 

#fitnesspodcast #ozempic #wegovy